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rates for each country, as well as relative risk rates for
vaccinated children, were entered into the model. Pri-
mary research was used in Canada, Germany, and the
United Kingdom to establish incidence rates for the
model. Incidence data for other countries was obtained
from published studies. Relative risk data for vaccination
was obtained from the Northern California Kaiser Per-
manente Efficacy Study. The following “health states”
were considered in the model: well, meningitis, bactere-
mia, pneumonia, otitis media, sinusitis, and death. A de-
cision tree model was developed for each “health state”
in each country, to evaluate the direct and indirect cost of
illness. Each decision tree model was based on a local
clinical management analysis and resource valuation. The
Markov model was adapted to accommodate five dosing
schedules of PCV, based on the age of initial vaccination.
The expected utilization of PCV in all child groups was
incorporated in a net budgetary impact analysis. RE-
SULTS: Cost-effectiveness, measured as the incremental
cost-per-life-year gained, varied by country. PCV is a
cost-effective method of disease prevention when consid-
ering the savings in direct and indirect costs and the high
efficacy demonstrated in invasive disease. CONCLU-
SIONS: PCV should be supported by healthcare provid-
ers in the six countries because it is the only means of
pneumococcal disease prevention in a high-risk popula-
tion and it is cost-effective.
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OBJECTIVE: To estimate the clinical and economic ben-
efits of the pneumoccocal conjugate vaccine (PCV) in
preventing acute otitis media (AOM), tympanostomy, and
community-acquired pneumonia (CAP) (“study events”)
in young children. METHODS: We developed a model of
the incidence to age 10 years of study events in children
5 years of age, and used it to examine the benefits of
vaccination in a hypothetical cohort of 1000 children.
We estimated the cumulative incidence and medical-care
costs (discounted at 3%) of study events in the absence of
vaccination using data from a large health plan; indirect
costs were not considered. Among children vaccinated at
ages 2 years, vaccination was assumed to reduce the
annual number of cases of AOM by 7% to age 2 years,
by 9.6% between ages 2–5 years, and by 4.8% thereafter.
Among children vaccinated at ages 24–59 months, the
AOM rate was assumed to be reduced by 9.6% for 3
years, and by 4.8% thereafter. Vaccination was similarly
assumed to reduce the annual rate of tympanostomy and
CAP by 20% and 11% respectively to age 5 years among
children vaccinated at ages 2 years, and for 3 years for
those vaccinated at ages 24–59 months; thereafter, pro-
tective efficacy was assumed to be 10% and 5.5% respec-
tively. RESULTS: Vaccination would reduce the cumula-
tive incidence of AOM (to age 10 years) by 163–376 cases
per 1000 children, tympanostomy by 8–22 cases per 1000,
and CAP by 14–31 cases per 1000. Total cumulative dis-
counted medical-care costs would be reduced by $30,000–
$74,000 per 1000. CONCLUSION: Routine vaccination
of young children with PCV would reduce the incidence
and costs of AOM, tympanostomy, and CAP.
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OBJECTIVE: Although efavirenz has demonstrated excel-
lent efficacy in clinical trials and is less expensive than most
regimens, a full understanding of its economic impact re-
quires knowledge of the effect key parameters have on the
economic situation. In this study, the costs of managing
HIV treatment naïve patients with efavirenz compared to
indinavir were evaluated. METHODS: A model was devel-
oped to simulate the disease progression of a population of
HIV patients. Data from a clinical trial comparing two
nucleoside reverse transcriptase inhibitors plus efavirenz to
a similar regimen containing indinavir provided effective-
ness inputs to the model. These data along with the likeli-
hood of viral rebound over time were used to project the
long-term effectiveness of initial treatment with these regi-
mens. Cost estimates were developed from six all-payer
state discharge databases, fee schedules, survey data and
the literature for different disease states in the progression
of HIV. Costs are reported in 1998 US dollars. RESULTS:
Over the 24 week trial period, patients beginning treatment
with an efavirenz regimen were predicted to cost $2672 less
than those started on an indinavir regimen. Efavirenz is
forecast to maintain cost savings through year 6 ($11,015)
given its intention-to-treat response rate of 75%. Only if
this rate were 30% of the demonstrated rate would indi-
navir therapy be less expensive over the first 3.2 years fol-
lowing treatment initiation at which time efavirenz
achieves cost savings. Other factors such as the cost of indi-
navir therapy will be discussed. CONCLUSIONS: The re-
sults of our model suggest that the health benefits associ-
ated with efavirenz treatment are achieved at a cost savings
relative to indinavir treatment. These results were found to
be quite robust to variation in key parameters.
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The widespread use of pediatric diphtheria, tetanus, and
pertussis vaccines has led to a dramatic decline in pertus-
sis. However, a resurgence of pertussis has recently been
observed, particularly among adolescents and adults,
now considered important sources of infections. The ad-
dition of an acellular pertussis component to the CDC-
recommended diphtheria and tetanus adult booster vac-
cine could reduce the occurrence of pertussis. Although
policy-makers will base their decisions on epidemiologi-
cal, clinical, and ethical grounds, they may also require
evidence of the economic value of this added component
before formulating a final immunization recommendation.
OBJECTIVES: To provide a preliminary assessment of
the economic value of vaccinating all new parents (or
guardians) at the time of birth of their first child. METH-
ODS: A literature-based decision analysis was developed
to estimate the clinical and epidemiological costs and
benefits of this vaccination strategy. The model projects
the number of—and the direct and indirect cost savings
associated with—mild, hospitalized, and fatal clinical
pertussis cases prevented in vaccinated adults and in non-
vaccinated children (due to herd immunity). RESULTS:
Our analysis suggests that such a vaccination strategy
could prevent 12,000 to 28,000, mostly adult, infections
and about 1000 hospitalizations annually. The results
also indicate that vaccination may be cost-effective, with
a cost per infection avoided ranging between $632 and
$1318. CONCLUSIONS: The results of this analysis sug-
gest that adult booster pertussis vaccination provides
substantial economic and clinical benefits. Policy makers
should not exclude adults from their recommendation
considerations until more definitive epidemiological and
economic data become available.
PHV18
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Studies have shown that combination interferonribavirin
is a cost-effective treatment for Hepatitis C from a soci-
etal perspective. Safety-net hospitals are currently faced
with the prospect of paying for an expensive treatment
for their many patients who are unable to pay. OBJEC-
TIVES: Examine the cost-effectiveness of alternative
treatment strategies for Hepatitis C as it affects the
safety-net hospital. METHODS: A Markov decision ana-
lytic model was constructed, using a reference case of a
45 year-old male with Hepatitis C, but without cirrhosis.
The perspective adopted was a safety-net hospital. Two
populations were examined: uninsured, and insured, but
without coverage for combination interferonribavirin.
Two strategies were considered: (1) CMB/G—Combina-
tion therapy for 6 or 12 months depending on virus gen-
otype, and (2) IFN/CMB, a cost saving strategy that be-
gins with 12 months of interferon monotherapy, followed
by 6 months of combination therapy for interferon re-
lapsers. Data came from prior publications. RESULTS:
In the uninsured group, CMB/G cost an additional $10,700
per patient, with an incremental cost-effectiveness ra-
tio(ICER) of $9600/QALY. Considering varying degrees
of aggressive disease (i.e., progression to cirrhosis), the
ICERs ranged from $6000/QALY–$12,100/QALY. In
the underinsured group, CMB/G was associated with an
additional cost of $13,100 per patient, with an ICER of
$11,700/QALY. For very aggressive disease, the ICER
for CMB/G dropped to $6900/QALY. For mild disease,
the ICER for CMB/G rose to $15,100/QALY. CON-
CLUSIONS: Although ICERs would appear to be cost-
effective from a societal perspective, this is less clear for
hospitals. Cost-saving strategies, such as starting with in-
terferon, and only giving combination therapy to relaps-
ers may be a necessary option for the safety-net hospital
struggling to find the funds to pay for treatment for their
large, indigent population.
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Antibiotics help reduce the economic burden of 600,000
annual hospitalizations and added outpatient visits and
days missed from work, school, and other activities due
to community-acquired pneumonia (CAP). OBJEC-
TIVES: To compare costs, outpatient visits, and 28-day
outcomes with gatifloxacin versus ceftriaxone among
adult patients with CAP. METHODS: Data were col-
lected on health care resource use from 287 inpatients
with CAP randomized to receive initial IV therapy with
either gatifloxacin alone (GAT) or ceftriaxone /
erythromycin (CEF). After at least two days of IV ther-
apy, patients could be switched to oral therapy with GAT
(GAT arm) or clarithromycin (CEF arm) at the treating
physician’s discretion. Total costs, which include medica-
tion, outpatient, and hospital costs, and the number of
outpatient visits and days missed from work, school, and
other activities were calculated. The analysis was limited
to clinically evaluable patients. RESULTS: A total of 205
patients were clinically evaluable (99 GAT, 106 CEF).
The mean total cost for the GAT arm was less than the
CEF arm ($5665 vs. $6469; P  0.149). The mean total
cost for patients admitted to the ICU was lower for pa-
tients.
